Wednesday, July 18, 2018
Company News: Page (1) of 1 - 06/25/18 Email this story to a friend. email article Print this page (Article printing at page facebook
Nordic Nanovector Appoints Eduardo Bravo as Chief Executive Officer
(June 25, 2018)

OSLO, 25 June, 2018 /PRNewswire/ --

Nordic Nanovector ASA (OSE: NANO) announces that Eduardo Bravo has been appointed as its Chief Executive Officer.

Mr. Bravo brings more than 25 years' experience in the biopharmaceutical industry and a strong track record in leading and growing international biotech and pharmaceutical organisations. Since 2011, as CEO of TiGenix, a dual-listed (Euronext Brussels and NASDAQ) biopharmaceutical company developing novel stem cell therapies, he successfully developed the company through several financing rounds, led its IPO on NASDAQ, and secured European marketing approval of its lead asset. In January 2018, Takeda Pharmaceutical Co. Ltd announced it was acquiring TiGenix for €520 million.

Prior to joining TiGenix' predecessor, Cellerix, in 2005, Mr Bravo held several senior management positions at Sanofi-Aventis and SmithKline Beecham. He is currently Chairman of Vivet Therapeutics. He holds a degree in Business Administration and an MBA (INSEAD).

Mr Bravo will take up the CEO position in Nordic Nanovector on 2 July and will be based in London, UK.

Ludvik Sandnes, Chairman of Nordic Nanovector's Board of Directors, said: "I am very pleased that we have attracted someone of Eduardo's calibre to become the CEO of Nordic Nanovector. He has extensive experience in corporate and product development, which is central to Nordic Nanovector's future success, and will provide excellent leadership under which the Company can continue to realise its significant potential with Betalutin®. I would also like to thank Tone Kvåle for supporting the company as Interim CEO over the past few months."

Eduardo Bravo added: "I am looking forward to this exciting new role as the CEO of Nordic Nanovector. It is clear that the Company has an exciting future based on the significant potential of Betalutin® in follicular lymphoma and NHL more broadly. I am joining an excellent board and management team and am confident that with my complementary experience and networks, we can succeed with Betalutin® to provide physicians with another treatment option to improve the lives of patients who are in dire need of effective therapies to control their disease and build significant value in the company."

On joining Nordic Nanovector, Mr Bravo will be granted 250,000 PSUs (performance share units) and the company's Board of Directors has undertaken to grant him a further 50,000 PSUs as part of the company's annual grant of PSUs in the first quarter of 2019. For further information about the PSUs and the related warrants, see pages 66-68 in the company's annual report for 2017. In addition, on joining Nordic Nanovector, Mr Bravo will receive a sign-on bonus of EUR 50,000 and has undertaken to invest, at minimum, the net amount after tax in Nordic Nanovector shares and will do so following this announcement.

For further information, please contact:

Ludvik Sandnes,
Cell: +47-907-43017
Email: [email protected]
International Media Enquiries

Mark Swallow/David Dible/Isabelle Andrews (Citigate Dewe Rogerson)
Tel: +44-207-638-9571
Email: [email protected] 

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at

This information was brought to you by Cision,c2556276


Cision View original content:

SOURCE Nordic Nanovector

Copyright 2014 PR Newswire. All Rights Reserved

Page: 1

Related Keywords:Disease,Cancer,Surgery,Science,Lifestyle,Medical,Biology,Stem Cell,Cancer,Business,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter

  • Healthcare IT Market 2018 - 2023 with SWOT Analysis regarding upcoming Changes and Technology Adaptations in Global Healthcare Sector
  • Robotics Prosthetics Market Exclusive Analysis by MRFR | Industry Growing with 9.5% CAGR up to 2027 | The Demand for Robotic Prosthetic is Found to be Increasing across the Globe
  • Implantable Medical Devices Market Predicted to be Worth US$ 49.8 Bn by 2024, Says TMR
  • Global Cosmetic Chemicals Industry
  • HMP's 8th Annual Amputation Prevention Symposium Expected to Draw 800 Clinicians to Chicago to Join the CLI Revolution

  • Camurus Announces PDUFA Date for CAM2038 for the Treatment of Opioid use Disorder
  • Omega-3 Market to Reach US$ 16.37 Bn by 2023, Globally -
  • Association of Community Cancer Centers and Advisory Board Launch 9th Annual Trends in Cancer Care Survey
  • Small Animal Imaging Market is Estimated to Grow at a Faster Pace With the Significant CAGR During the Forecast Period: Radiant Insights, Inc.
  • Presage Biosciences Closes Series D Financing with Takeda and Celgene, and Announces Appointment of Richard Klinghoffer, PhD as Chief Executive Officer

    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines